Jyong Biotech Ltd. Ordinary Shares
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $156.6M
- Price
- $2.06
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.98%
- Volume
- 26.8K
About
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Quick stats
Shares outstanding76.0M
Computed float31.1M
Float / shares40.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001954488
Websitehttps://www.jyongbio.com/
AI Summary
AI-generated1/8
minorneutralother
Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow
Jyong Biotech (Nasdaq: MENS) announced it will participate in the StockFan Virtual Investor Non-Deal Roadshow on Sunday, September 6, 2026 (U.S. Eastern Time), with the corresponding Taipei session on Monday, September 7.
The hour-long virtual event will be conducted in both Mandarin Chinese and English, hosted via Zoom with advance registration, and is timed to accommodate the company's global investor base.
The release contains no new financial, clinical, or regulatory updates; Jyong's pipeline description is unchanged, with BOTRESO remaining its primary botanical drug candidate targeting urinary system diseases.